Stephen J. Forman,


Hematologist-Oncologist, Director, Hematologic Malignancies Research Institute


It remains a privilege, after 45 years of doing this, to be allowed to take care of somebody who has these diseases.

City of Hope Duarte
1500 East Duarte Road
Duarte, CA 91010
Hematologic Oncology
Medical school:

1974, M.D., Medicine, University of Southern California, Los Angeles, CA


1974-1975, Harbor UCLA Hospital, Torrance, CA


1979-1980, Fellow, Medical Oncology, City of Hope, Duarte, CA

1978-1979, Research Associate, Hematology Division, Department of Pharmacology, Los Angeles County+USC Medical Center, Los Angeles, CA

1976-1978, Fellow, Hematology Division, LAC+USC Medical Center, Los Angeles, CA

About Me

Stephen J. Forman, M.D., is an international expert in leukemia, lymphoma and bone marrow transplantation. Dr. Forman is also co-editor of "Thomas’ Hematopoietic Cell Transplantation," a definitive textbook for clinicians, scientists and health care professionals.

Dr. Forman exudes the special blend of zealous determination and compassion typical of City of Hope team members, illustrated by his own words: “We come to work every day thinking ‘cure ...’ Once we've extended our hand and grabbed yours, we don't let it go.”

In 45 years at City of Hope, Dr. Forman has been instrumental in dramatically advancing survival rates for blood disorders. He is deeply involved with the translational and clinical research at City of Hope's Toni Stephenson Lymphoma Center, Cellular Immunotherapy Center, Judy and Bernard Briskin Center for Multiple Myeloma Research and the Gehr Family Center for Leukemia Research.

His current projects are focused on immunotherapy — using the body's own immune system to attack cancer. Much of his current work centers on T cells and their cancer-fighting potential.

Patient ratings
Star ratings and comments are only available for medical, radiation and gynecologic oncologists. Gynecologic surgical offerings are not included at this time due to a different survey tool required to evaluate these services. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy at our comprehensive care and research centers. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.